1
|
Asplund O, Storm P, Chandra V, Hatem G, Ottosson-Laakso E, Mansour-Aly D, Krus U, Ibrahim H, Ahlqvist E, Tuomi T, Renström E, Korsgren O, Wierup N, Ibberson M, Solimena M, Marchetti P, Wollheim C, Artner I, Mulder H, Hansson O, Otonkoski T, Groop L, Prasad RB. Islet Gene View-a tool to facilitate islet research. Life Sci Alliance 2022; 5:e202201376. [PMID: 35948367 PMCID: PMC9366203 DOI: 10.26508/lsa.202201376] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2022] [Revised: 07/18/2022] [Accepted: 07/18/2022] [Indexed: 01/27/2023] Open
Abstract
Characterization of gene expression in pancreatic islets and its alteration in type 2 diabetes (T2D) are vital in understanding islet function and T2D pathogenesis. We leveraged RNA sequencing and genome-wide genotyping in islets from 188 donors to create the Islet Gene View (IGW) platform to make this information easily accessible to the scientific community. Expression data were related to islet phenotypes, diabetes status, other islet-expressed genes, islet hormone-encoding genes and for expression in insulin target tissues. The IGW web application produces output graphs for a particular gene of interest. In IGW, 284 differentially expressed genes (DEGs) were identified in T2D donor islets compared with controls. Forty percent of DEGs showed cell-type enrichment and a large proportion significantly co-expressed with islet hormone-encoding genes; glucagon (<i>GCG</i>, 56%), amylin (<i>IAPP</i>, 52%), insulin (<i>INS</i>, 44%), and somatostatin (<i>SST</i>, 24%). Inhibition of two DEGs, <i>UNC5D</i> and <i>SERPINE2</i>, impaired glucose-stimulated insulin secretion and impacted cell survival in a human β-cell model. The exploratory use of IGW could help designing more comprehensive functional follow-up studies and serve to identify therapeutic targets in T2D.
Collapse
Affiliation(s)
- Olof Asplund
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
| | - Petter Storm
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
- Department of Experimental Medical Science, Developmental and Regenerative Neurobiology, Wallenberg Neuroscience Center, Lund, Sweden
| | - Vikash Chandra
- Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland
| | - Gad Hatem
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
| | - Emilia Ottosson-Laakso
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
| | - Dina Mansour-Aly
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
| | - Ulrika Krus
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
| | - Hazem Ibrahim
- Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland
| | - Emma Ahlqvist
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
| | - Tiinamaija Tuomi
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
- Department of Endocrinology, Abdominal Centre, Helsinki University Hospital, Folkhalsan Research Center, Helsinki, Finland
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
| | - Erik Renström
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
| | - Olle Korsgren
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
- Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden
| | - Nils Wierup
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
| | - Mark Ibberson
- Vital-IT Group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland
| | - Michele Solimena
- Paul Langerhans Institute Dresden of the Helmholtz Center, Munich at University Hospital Carl Gustav Carus and Faculty of Medicine, TU Dresden, Dresden, Germany
- German Center for Diabetes Research (DZD), Munich, Germany
- Max Planck Institute of Molecular Cell Biology and Genetics, (MPI-CBG), Dresden, Germany
| | - Piero Marchetti
- Department of Clinical and Experimental Medicine, Cisanello, University Hospital, University of Pisa, Pisa, Italy
| | - Claes Wollheim
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
- Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Isabella Artner
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
| | - Hindrik Mulder
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
| | - Ola Hansson
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
| | - Timo Otonkoski
- Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland
- Children's Hospital, Helsinki University Hospital, Helsinki, Finland
| | - Leif Groop
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
| | - Rashmi B Prasad
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
- Human Tissue Laboratory at Lund University Diabetes Centre, Lund, Sweden
| |
Collapse
|
2
|
Chriett S, Lindqvist A, Shcherbina L, Edlund A, Abels M, Asplund O, Martínez López JA, Ottosson-Laakso E, Hatem G, Prasad RB, Groop L, Eliasson L, Hansson O, Wierup N. SCRT1 is a novel beta cell transcription factor with insulin regulatory properties. Mol Cell Endocrinol 2021; 521:111107. [PMID: 33309639 DOI: 10.1016/j.mce.2020.111107] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/05/2020] [Revised: 11/13/2020] [Accepted: 11/30/2020] [Indexed: 01/06/2023]
Abstract
Here we show that scratch family transcriptional repressor 1 (SCRT1), a zinc finger transcriptional regulator, is a novel regulator of beta cell function. SCRT1 was found to be expressed in beta cells in rodent and human islets. In human islets, expression of SCRT1 correlated with insulin secretion capacity and the expression of the insulin (INS) gene. Furthermore, SCRT1 mRNA expression was lower in beta cells from T2D patients. siRNA-mediated Scrt1 silencing in INS-1832/13 cells, mouse- and human islets resulted in impaired glucose-stimulated insulin secretion and decreased expression of the insulin gene. This is most likely due to binding of SCRT1 to E-boxes of the Ins1 gene as shown with ChIP. Scrt1 silencing also reduced the expression of several key beta cell transcription factors. Moreover, Scrt1 mRNA expression was reduced by glucose and SCRT1 protein was found to translocate between the nucleus and the cytosol in a glucose-dependent fashion in INS-1832/13 cells as well as in a rodent model of T2D. SCRT1 was also regulated by a GSK3β-dependent SCRT1-serine phosphorylation. Taken together, SCRT1 is a novel beta cell transcription factor that regulates insulin secretion and is affected in T2D.
Collapse
Affiliation(s)
- S Chriett
- Lund University Diabetes Centre, Malmö, Sweden
| | - A Lindqvist
- Lund University Diabetes Centre, Malmö, Sweden
| | | | - A Edlund
- Lund University Diabetes Centre, Malmö, Sweden
| | - M Abels
- Lund University Diabetes Centre, Malmö, Sweden
| | - O Asplund
- Lund University Diabetes Centre, Malmö, Sweden
| | - J A Martínez López
- Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
| | | | - G Hatem
- Lund University Diabetes Centre, Malmö, Sweden
| | - R B Prasad
- Lund University Diabetes Centre, Malmö, Sweden
| | - L Groop
- Lund University Diabetes Centre, Malmö, Sweden; Finnish Institute of Molecular Medicine, Helsinki, Finland
| | - L Eliasson
- Lund University Diabetes Centre, Malmö, Sweden
| | - O Hansson
- Lund University Diabetes Centre, Malmö, Sweden; Finnish Institute of Molecular Medicine, Helsinki, Finland
| | - N Wierup
- Lund University Diabetes Centre, Malmö, Sweden.
| |
Collapse
|
3
|
Ottosson-Laakso E, Krus U, Storm P, Prasad RB, Oskolkov N, Ahlqvist E, Fadista J, Hansson O, Groop L, Vikman P. Glucose-Induced Changes in Gene Expression in Human Pancreatic Islets: Causes or Consequences of Chronic Hyperglycemia. Diabetes 2017; 66:3013-3028. [PMID: 28882899 DOI: 10.2337/db17-0311] [Citation(s) in RCA: 52] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/12/2017] [Accepted: 08/30/2017] [Indexed: 11/13/2022]
Abstract
Dysregulation of gene expression in islets from patients with type 2 diabetes (T2D) might be causally involved in the development of hyperglycemia, or it could develop as a consequence of hyperglycemia (i.e., glucotoxicity). To separate the genes that could be causally involved in pathogenesis from those likely to be secondary to hyperglycemia, we exposed islets from human donors to normal or high glucose concentrations for 24 h and analyzed gene expression. We compared these findings with gene expression in islets from donors with normal glucose tolerance and hyperglycemia (including T2D). The genes whose expression changed in the same direction after short-term glucose exposure, as in T2D, were considered most likely to be a consequence of hyperglycemia. Genes whose expression changed in hyperglycemia but not after short-term glucose exposure, particularly those that also correlated with insulin secretion, were considered the strongest candidates for causal involvement in T2D. For example, ERO1LB, DOCK10, IGSF11, and PRR14L were downregulated in donors with hyperglycemia and correlated positively with insulin secretion, suggesting a protective role, whereas TMEM132C was upregulated in hyperglycemia and correlated negatively with insulin secretion, suggesting a potential pathogenic role. This study provides a catalog of gene expression changes in human pancreatic islets after exposure to glucose.
Collapse
Affiliation(s)
- Emilia Ottosson-Laakso
- Lund University Diabetes Centre, Department of Clinical Sciences, Lund University, Malmö, Sweden
| | - Ulrika Krus
- Lund University Diabetes Centre, Department of Clinical Sciences, Lund University, Malmö, Sweden
| | - Petter Storm
- Lund University Diabetes Centre, Department of Clinical Sciences, Lund University, Malmö, Sweden
| | - Rashmi B Prasad
- Lund University Diabetes Centre, Department of Clinical Sciences, Lund University, Malmö, Sweden
| | - Nikolay Oskolkov
- Lund University Diabetes Centre, Department of Clinical Sciences, Lund University, Malmö, Sweden
| | - Emma Ahlqvist
- Lund University Diabetes Centre, Department of Clinical Sciences, Lund University, Malmö, Sweden
| | - João Fadista
- Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark
| | - Ola Hansson
- Lund University Diabetes Centre, Department of Clinical Sciences, Lund University, Malmö, Sweden
| | - Leif Groop
- Lund University Diabetes Centre, Department of Clinical Sciences, Lund University, Malmö, Sweden
- Finnish Institute of Molecular Medicine, University of Helsinki, Helsinki, Finland
| | - Petter Vikman
- Lund University Diabetes Centre, Department of Clinical Sciences, Lund University, Malmö, Sweden
| |
Collapse
|
4
|
Almgren P, Lindqvist A, Krus U, Hakaste L, Ottosson-Laakso E, Asplund O, Sonestedt E, Prasad RB, Laurila E, Orho-Melander M, Melander O, Tuomi T, Holst JJ, Nilsson PM, Wierup N, Groop L, Ahlqvist E. Genetic determinants of circulating GIP and GLP-1 concentrations. JCI Insight 2017; 2:93306. [PMID: 29093273 DOI: 10.1172/jci.insight.93306] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2017] [Accepted: 09/29/2017] [Indexed: 12/19/2022] Open
Abstract
The secretion of insulin and glucagon from the pancreas and the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) from the gastrointestinal tract is essential for glucose homeostasis. Several novel treatment strategies for type 2 diabetes (T2D) mimic GLP-1 actions or inhibit incretin degradation (DPP4 inhibitors), but none is thus far aimed at increasing the secretion of endogenous incretins. In order to identify new potential therapeutic targets for treatment of T2D, we performed a meta-analysis of a GWAS and an exome-wide association study of circulating insulin, glucagon, GIP, and GLP-1 concentrations measured during an oral glucose tolerance test in up to 7,828 individuals. We identified 6 genome-wide significant functional loci associated with plasma incretin concentrations in or near the SLC5A1 (encoding SGLT1), GIPR, ABO, GLP2R, F13A1, and HOXD1 genes and studied the effect of these variants on mRNA expression in pancreatic islet and on metabolic phenotypes. Immunohistochemistry showed expression of GIPR, ABO, and HOXD1 in human enteroendocrine cells and expression of ABO in pancreatic islets, supporting a role in hormone secretion. This study thus provides candidate genes and insight into mechanisms by which secretion and breakdown of GIP and GLP-1 are regulated.
Collapse
Affiliation(s)
- Peter Almgren
- Lund University Diabetes Centre, Department of Clinical Sciences, Malmö, Lund University, Skåne University Hospital, Malmö, Sweden
| | - Andreas Lindqvist
- Lund University Diabetes Centre, Department of Clinical Sciences, Malmö, Lund University, Skåne University Hospital, Malmö, Sweden
| | - Ulrika Krus
- Lund University Diabetes Centre, Department of Clinical Sciences, Malmö, Lund University, Skåne University Hospital, Malmö, Sweden
| | - Liisa Hakaste
- Endocrinology, Abdominal Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Diabetes and Obesity Research Program, University of Helsinki and Folkhälsan Research Center, Helsinki, Finland
| | - Emilia Ottosson-Laakso
- Lund University Diabetes Centre, Department of Clinical Sciences, Malmö, Lund University, Skåne University Hospital, Malmö, Sweden
| | - Olof Asplund
- Lund University Diabetes Centre, Department of Clinical Sciences, Malmö, Lund University, Skåne University Hospital, Malmö, Sweden
| | - Emily Sonestedt
- Lund University Diabetes Centre, Department of Clinical Sciences, Malmö, Lund University, Skåne University Hospital, Malmö, Sweden
| | - Rashmi B Prasad
- Lund University Diabetes Centre, Department of Clinical Sciences, Malmö, Lund University, Skåne University Hospital, Malmö, Sweden
| | - Esa Laurila
- Lund University Diabetes Centre, Department of Clinical Sciences, Malmö, Lund University, Skåne University Hospital, Malmö, Sweden
| | - Marju Orho-Melander
- Lund University Diabetes Centre, Department of Clinical Sciences, Malmö, Lund University, Skåne University Hospital, Malmö, Sweden
| | - Olle Melander
- Lund University Diabetes Centre, Department of Clinical Sciences, Malmö, Lund University, Skåne University Hospital, Malmö, Sweden
| | - Tiinamaija Tuomi
- Endocrinology, Abdominal Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Diabetes and Obesity Research Program, University of Helsinki and Folkhälsan Research Center, Helsinki, Finland.,Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland
| | - Jens Juul Holst
- Novo Nordisk Foundation Center for Basic Metabolic Research and Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Peter M Nilsson
- Clinical Research Unit Medicine, Department of Internal Medicine, and Department of Clinical Sciences, Malmö, Lund University, Skåne University Hospital, Malmö, Sweden
| | - Nils Wierup
- Lund University Diabetes Centre, Department of Clinical Sciences, Malmö, Lund University, Skåne University Hospital, Malmö, Sweden
| | - Leif Groop
- Lund University Diabetes Centre, Department of Clinical Sciences, Malmö, Lund University, Skåne University Hospital, Malmö, Sweden.,Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland
| | - Emma Ahlqvist
- Lund University Diabetes Centre, Department of Clinical Sciences, Malmö, Lund University, Skåne University Hospital, Malmö, Sweden
| |
Collapse
|
5
|
Shcherbina L, Edlund A, Esguerra JLS, Abels M, Zhou Y, Ottosson-Laakso E, Wollheim CB, Hansson O, Eliasson L, Wierup N. Endogenous beta-cell CART regulates insulin secretion and transcription of beta-cell genes. Mol Cell Endocrinol 2017; 447:52-60. [PMID: 28237718 DOI: 10.1016/j.mce.2017.02.027] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/14/2016] [Revised: 02/16/2017] [Accepted: 02/16/2017] [Indexed: 01/20/2023]
Abstract
Impaired beta-cell function is key to the development of type 2 diabetes. Cocaine- and amphetamine-regulated transcript (CART) is an islet peptide with insulinotropic and glucagonostatic properties. Here we studied the role of endogenous CART in beta-cell function. CART silencing in INS-1 (832/13) beta-cells reduced insulin secretion and production, ATP levels and beta-cell exocytosis. This was substantiated by reduced expression of several exocytosis genes, as well as reduced expression of genes important for insulin secretion and processing. In addition, CART silencing reduced the expression of a network of transcription factors essential for beta-cell function. Moreover, in RNAseq data from human islet donors, CARTPT expression levels correlated with insulin, exocytosis genes and key beta-cell transcription factors. Thus, endogenous beta-cell CART regulates insulin expression and secretion in INS-1 (832/13) cells, via actions on the exocytotic machinery and a network of beta-cell transcription factors. We conclude that CART is important for maintaining the beta-cell phenotype.
Collapse
Affiliation(s)
- L Shcherbina
- Lund University Diabetes Centre, Skåne University Hospital, Jan Waldenströms Gata 35, 214 28 Malmö, Sweden
| | - A Edlund
- Lund University Diabetes Centre, Skåne University Hospital, Jan Waldenströms Gata 35, 214 28 Malmö, Sweden
| | - J L S Esguerra
- Lund University Diabetes Centre, Skåne University Hospital, Jan Waldenströms Gata 35, 214 28 Malmö, Sweden
| | - M Abels
- Lund University Diabetes Centre, Skåne University Hospital, Jan Waldenströms Gata 35, 214 28 Malmö, Sweden
| | - Y Zhou
- Lund University Diabetes Centre, Skåne University Hospital, Jan Waldenströms Gata 35, 214 28 Malmö, Sweden
| | - E Ottosson-Laakso
- Lund University Diabetes Centre, Skåne University Hospital, Jan Waldenströms Gata 35, 214 28 Malmö, Sweden
| | - C B Wollheim
- Lund University Diabetes Centre, Skåne University Hospital, Jan Waldenströms Gata 35, 214 28 Malmö, Sweden; Department of Cell Physiology and Metabolism, University Medical Center, 1 Rue Michel-Servet, CH-1211 Genève 4, Switzerland
| | - O Hansson
- Lund University Diabetes Centre, Skåne University Hospital, Jan Waldenströms Gata 35, 214 28 Malmö, Sweden
| | - L Eliasson
- Lund University Diabetes Centre, Skåne University Hospital, Jan Waldenströms Gata 35, 214 28 Malmö, Sweden
| | - N Wierup
- Lund University Diabetes Centre, Skåne University Hospital, Jan Waldenströms Gata 35, 214 28 Malmö, Sweden.
| |
Collapse
|
6
|
Bennet H, Mollet IG, Balhuizen A, Medina A, Nagorny C, Bagge A, Fadista J, Ottosson-Laakso E, Vikman P, Dekker-Nitert M, Eliasson L, Wierup N, Artner I, Fex M. Serotonin (5-HT) receptor 2b activation augments glucose-stimulated insulin secretion in human and mouse islets of Langerhans. Diabetologia 2016; 59:744-54. [PMID: 26733006 DOI: 10.1007/s00125-015-3847-6] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/18/2015] [Accepted: 12/04/2015] [Indexed: 12/22/2022]
Abstract
AIMS/HYPOTHESIS The Gq-coupled 5-hydroxytryptamine 2B (5-HT2B) receptor is known to regulate the proliferation of islet beta cells during pregnancy. However, the role of serotonin in the control of insulin release is still controversial. The aim of the present study was to explore the role of the 5-HT2B receptor in the regulation of insulin secretion in mouse and human islets, as well as in clonal INS-1(832/13) cells. METHODS Expression of HTR2B mRNA and 5-HT2B protein was examined with quantitative real-time PCR, RNA sequencing and immunohistochemistry. α-Methyl serotonin maleate salt (AMS), a serotonin receptor agonist, was employed for robust 5-HT2B receptor activation. Htr2b was silenced with small interfering RNA in INS-1(832/13) cells. Insulin secretion, Ca(2+) response and oxygen consumption rate were determined. RESULTS Immunohistochemistry revealed that 5-HT2B is expressed in human and mouse islet beta cells. Activation of 5-HT2B receptors by AMS enhanced glucose-stimulated insulin secretion (GSIS) in human and mouse islets as well as in INS-1(832/13) cells. Silencing Htr2b in INS-1(832/13) cells led to a 30% reduction in GSIS. 5-HT2B receptor activation produced robust, regular and sustained Ca(2+) oscillations in mouse islets with an increase in both peak distance (period) and time in the active phase as compared with control. Enhanced insulin secretion and Ca(2+) changes induced by AMS coincided with an increase in oxygen consumption in INS-1(832/13) cells. CONCLUSIONS/INTERPRETATION Activation of 5-HT2B receptors stimulates GSIS in beta cells by triggering downstream changes in cellular Ca(2+) flux that enhance mitochondrial metabolism. Our findings suggest that serotonin and the 5-HT2B receptor stimulate insulin release.
Collapse
Affiliation(s)
- Hedvig Bennet
- Lund University Diabetes Centre, Department of Clinical Sciences, Unit of Diabetes and Celiac disease, Clinical Research Centre, Jan Waldenströms gata 35, Clinical Research Centre House 91:10, Skåne University Hospital Malmö, SE-20502, Malmö, Sweden.
| | - Inês G Mollet
- Lund University Diabetes Centre, Islet Cell Exocytosis, Malmö, Sweden
| | - Alexander Balhuizen
- Lund University Diabetes Centre, Department of Clinical Sciences, Unit of Diabetes and Celiac disease, Clinical Research Centre, Jan Waldenströms gata 35, Clinical Research Centre House 91:10, Skåne University Hospital Malmö, SE-20502, Malmö, Sweden
| | - Anya Medina
- Lund University Diabetes Centre, Department of Clinical Sciences, Unit of Diabetes and Celiac disease, Clinical Research Centre, Jan Waldenströms gata 35, Clinical Research Centre House 91:10, Skåne University Hospital Malmö, SE-20502, Malmö, Sweden
| | - Cecilia Nagorny
- Lund University Diabetes Centre, Molecular Metabolism, Malmö, Sweden
| | - Annika Bagge
- Lund University Diabetes Centre, Molecular Metabolism, Malmö, Sweden
| | - Joao Fadista
- Lund University Diabetes Centre, Diabetes and Endocrinology, Malmö, Sweden
| | | | - Petter Vikman
- Lund University Diabetes Centre, Diabetes and Endocrinology, Malmö, Sweden
| | - Marloes Dekker-Nitert
- Lund University Diabetes Centre, Diabetes and Endocrinology, Malmö, Sweden
- Royal Brisbane Clinical School, UQ Centre for Clinical Research, The University of Queensland, Herston, QLD, Australia
| | - Lena Eliasson
- Lund University Diabetes Centre, Islet Cell Exocytosis, Malmö, Sweden
| | - Nils Wierup
- Lund University Diabetes Centre, Neuroendocrine Cell Biology, Malmö, Sweden
| | - Isabella Artner
- Lund University Diabetes Centre, Stem Cell Center, Biomedical Centre (BMC), Lund, Sweden
| | - Malin Fex
- Lund University Diabetes Centre, Department of Clinical Sciences, Unit of Diabetes and Celiac disease, Clinical Research Centre, Jan Waldenströms gata 35, Clinical Research Centre House 91:10, Skåne University Hospital Malmö, SE-20502, Malmö, Sweden
| |
Collapse
|
7
|
Ottosson-Laakso E, Tuomi T, Forsén B, Gullström M, Groop PH, Groop L, Vikman P. Influence of Familial Renal Glycosuria Due to Mutations in the SLC5A2 Gene on Changes in Glucose Tolerance over Time. PLoS One 2016; 11:e0146114. [PMID: 26735923 PMCID: PMC4703216 DOI: 10.1371/journal.pone.0146114] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2015] [Accepted: 12/14/2015] [Indexed: 12/30/2022] Open
Abstract
Familial renal glycosuria is an inherited disorder resulting in glucose excretion in the urine despite normal blood glucose concentrations. It is most commonly due to mutations in the SLC5A2 gene coding for the glucose transporter SGLT2 in the proximal tubule. Several drugs have been introduced as means to lower glucose in patients with type 2 diabetes targeting SGLT2 resulting in renal glycosuria, but no studies have addressed the potential effects of decreased renal glucose reabsorption and chronic glycosuria on the prevention of glucose intolerance. Here we present data on a large pedigree with renal glycosuria due to two mutations (c.300-303+2del and p.A343V) in the SLC5A2 gene. The mutations, which in vitro affected glucose transport in a cell line model, and the ensuing glycosuria were not associated with better glycemic control during a follow-up period of more than 10 years. One individual, who was compound heterozygous for mutations in the SLC5A2 gene suffered from severe urogenital candida infections and postprandial hypoglycemia. In conclusion, in this family with familial glycosuria we did not find any evidence that chronic loss of glucose in the urine would protect from deterioration of the glucose tolerance over time.
Collapse
Affiliation(s)
- Emilia Ottosson-Laakso
- Diabetes and Endocrinology, Department of Clinical Sciences, Lund University, Malmö, Sweden
- * E-mail:
| | - Tiinamaija Tuomi
- Folkhälsan Institute of Genetics, Folkhälsan Research Centre, Biomedicum, Helsinki, Finland
- Research Program Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland
- Finnish Institute of Molecular Medicine, University of Helsinki, Helsinki, Finland
| | | | | | - Per-Henrik Groop
- Folkhälsan Institute of Genetics, Folkhälsan Research Centre, Biomedicum, Helsinki, Finland
- Research Program Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland
- Abdominal Center Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
- Baker IDI Heart and Diabetes Institute, Melbourne, Australia
| | - Leif Groop
- Diabetes and Endocrinology, Department of Clinical Sciences, Lund University, Malmö, Sweden
- Finnish Institute of Molecular Medicine, University of Helsinki, Helsinki, Finland
| | - Petter Vikman
- Diabetes and Endocrinology, Department of Clinical Sciences, Lund University, Malmö, Sweden
| |
Collapse
|
8
|
Taneera J, Fadista J, Ahlqvist E, Atac D, Ottosson-Laakso E, Wollheim CB, Groop L. Identification of novel genes for glucose metabolism based upon expression pattern in human islets and effect on insulin secretion and glycemia. Hum Mol Genet 2014; 24:1945-55. [PMID: 25489054 DOI: 10.1093/hmg/ddu610] [Citation(s) in RCA: 76] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
Normal glucose homeostasis is characterized by appropriate insulin secretion and low HbA1c. Gene expression signatures associated with these two phenotypes could be essential for islet function and pathophysiology of type 2 diabetes (T2D). Herein, we employed a novel approach to identify candidate genes involved in T2D by correlating islet microarray gene expression data (78 donors) with insulin secretion and HbA1c level. The expression of 649 genes (P < 0.05) was correlated with insulin secretion and HbA1c. Of them, five genes (GLR1A, PPP1R1A, PLCDXD3, FAM105A and ENO2) correlated positively with insulin secretion/negatively with HbA1c and one gene (GNG5) correlated negatively with insulin secretion/positively with HbA1c were followed up. The five positively correlated genes have lower expression levels in diabetic islets, whereas GNG5 expression is higher. Exposure of human islets to high glucose for 24 h resulted in up-regulation of GNG5 and PPP1R1A expression, whereas the expression of ENO2 and GLRA1 was down-regulated. No effect was seen on the expression of FAM105A and PLCXD3. siRNA silencing in INS-1 832/13 cells showed reduction in insulin secretion for PPP1R1A, PLXCD3, ENO2, FAM105A and GNG5 but not GLRA1. Although no SNP in these gene loci passed the genome-wide significance for association with T2D in DIAGRAM+ database, four SNPs influenced gene expression in cis in human islets. In conclusion, we identified and confirmed PPP1R1A, FAM105A, ENO2, PLCDX3 and GNG5 as potential regulators of islet function. We provide a list of candidate genes as a resource for exploring their role in the pathogenesis of T2D.
Collapse
Affiliation(s)
- Jalal Taneera
- Department of Clinical Sciences, Diabetes and Endocrinology, Lund University Diabetes Centre, Skåne University Hospital, Lund University, 205 02 Malmö, Sweden
| | - Joao Fadista
- Department of Clinical Sciences, Diabetes and Endocrinology, Lund University Diabetes Centre, Skåne University Hospital, Lund University, 205 02 Malmö, Sweden
| | - Emma Ahlqvist
- Department of Clinical Sciences, Diabetes and Endocrinology, Lund University Diabetes Centre, Skåne University Hospital, Lund University, 205 02 Malmö, Sweden
| | - David Atac
- Department of Clinical Sciences, Diabetes and Endocrinology, Lund University Diabetes Centre, Skåne University Hospital, Lund University, 205 02 Malmö, Sweden
| | - Emilia Ottosson-Laakso
- Department of Clinical Sciences, Diabetes and Endocrinology, Lund University Diabetes Centre, Skåne University Hospital, Lund University, 205 02 Malmö, Sweden
| | - Claes B Wollheim
- Department of Clinical Sciences, Diabetes and Endocrinology, Lund University Diabetes Centre, Skåne University Hospital, Lund University, 205 02 Malmö, Sweden Department of Cell Physiology and Metabolism, Université de Genève, University Medical Centre, 1 rue Michel-Servet, Geneva 4 1211, Switzerland
| | - Leif Groop
- Department of Clinical Sciences, Diabetes and Endocrinology, Lund University Diabetes Centre, Skåne University Hospital, Lund University, 205 02 Malmö, Sweden
| |
Collapse
|
9
|
Zhou Y, Park SY, Su J, Bailey K, Ottosson-Laakso E, Shcherbina L, Oskolkov N, Zhang E, Thevenin T, Fadista J, Bennet H, Vikman P, Wierup N, Fex M, Rung J, Wollheim C, Nobrega M, Renström E, Groop L, Hansson O. TCF7L2 is a master regulator of insulin production and processing. Hum Mol Genet 2014; 23:6419-31. [PMID: 25015099 PMCID: PMC4240194 DOI: 10.1093/hmg/ddu359] [Citation(s) in RCA: 133] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Genome-wide association studies have revealed >60 loci associated with type 2 diabetes (T2D), but the underlying causal variants and functional mechanisms remain largely elusive. Although variants in TCF7L2 confer the strongest risk of T2D among common variants by presumed effects on islet function, the molecular mechanisms are not yet well understood. Using RNA-sequencing, we have identified a TCF7L2-regulated transcriptional network responsible for its effect on insulin secretion in rodent and human pancreatic islets. ISL1 is a primary target of TCF7L2 and regulates proinsulin production and processing via MAFA, PDX1, NKX6.1, PCSK1, PCSK2 and SLC30A8, thereby providing evidence for a coordinated regulation of insulin production and processing. The risk T-allele of rs7903146 was associated with increased TCF7L2 expression, and decreased insulin content and secretion. Using gene expression profiles of 66 human pancreatic islets donors’, we also show that the identified TCF7L2-ISL1 transcriptional network is regulated in a genotype-dependent manner. Taken together, these results demonstrate that not only synthesis of proinsulin is regulated by TCF7L2 but also processing and possibly clearance of proinsulin and insulin. These multiple targets in key pathways may explain why TCF7L2 has emerged as the gene showing one of the strongest associations with T2D.
Collapse
Affiliation(s)
- Yuedan Zhou
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden
| | | | - Jing Su
- European Bioinformatics Institute, Functional Genomics, Hinxton, Cambridge CB10 1SD, UK
| | - Kathleen Bailey
- Department of Human Genetics, University of Chicago, IL 60637, USA
| | | | - Liliya Shcherbina
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden
| | - Nikolay Oskolkov
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden
| | - Enming Zhang
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden
| | - Thomas Thevenin
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden
| | - João Fadista
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden
| | - Hedvig Bennet
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden
| | - Petter Vikman
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden
| | - Nils Wierup
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden
| | - Malin Fex
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden
| | - Johan Rung
- Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala 75185, Sweden and
| | - Claes Wollheim
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden, Department of Cell Physiology and Metabolism, Université de Genève, University Medical Centre, 1 rue Michel-Servet, Geneva 4 1211, Switzerland
| | - Marcelo Nobrega
- Department of Human Genetics, University of Chicago, IL 60637, USA
| | - Erik Renström
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden
| | - Leif Groop
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden
| | - Ola Hansson
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden,
| |
Collapse
|